The role of nebulized therapy in the management of COPD: Evidence and recommendations

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 9, Issue 1, 2012, Pages 58-72

  Dhand, Rajiv ^a   Dolovich, Myrna ^b   Chipps, Bradley ^c   Myers, Timothy R ^d   Restrepo, Ruben ^e   Rosen Farrar, Judith ^f  

^a University of Missouri   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c Capital Allergy and Respiratory Disease Center   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f Life Sciences Press   (United States)

Author keywords

Aerosol drug delivery device (ADDD); Aerosols; Chronic obstructive pulmonary disease (COPD); Dry powder inhaler (DPI); Exacerbations; Inhaler; Nebulizer; Pressurized metered dose inhaler (pMDI)

Indexed keywords

ARFORMOTEROL; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FENOTEROL; FLUNISOLIDE; FORMOTEROL; FORMOTEROL FUMARATE; IPRATROPIUM BROMIDE; LEVALBUTEROL; ORCIPRENALINE; OXITROPIUM BROMIDE; PLACEBO; PREDNISOLONE; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE;

AEROSOL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG MEGADOSE; HUMAN; JET NEBULIZER; LOW DRUG DOSE; LUNG FUNCTION; MAINTENANCE THERAPY; METERED DOSE INHALER; NEBULIZATION; NEBULIZER; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POWDER INHALER; PRESSURIZED METERED DOSE INHALER; PRIORITY JOURNAL; REVIEW; TREMOR; ULTRASONIC NEBULIZER; UNSPECIFIED SIDE EFFECT; VIBRATING MESH NEBULIZER;

ADRENAL CORTEX HORMONES; AIRWAY RESISTANCE; BRONCHODILATOR AGENTS; COGNITION DISORDERS; DELAYED-ACTION PREPARATIONS; EQUIPMENT DESIGN; HUMANS; MEDICATION ADHERENCE; MEDICATION ERRORS; NEBULIZERS AND VAPORIZERS; PATIENT EDUCATION AS TOPIC; PATIENT PREFERENCE; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84856595409     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2011.630047     Document Type: Review

References (108)

1. Global Initiative for Asthma (GINA), National Heart, Lung and Blood Institute, National Institutes of Health: GINA Report, Global Strategy for Asthma management and prevention, November 2006. Available at http://www.ginasthma.com. Accessed January 2011.
2. National Asthma Education and Prevention Program, National Institutes of Health: Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. Bethesda, MD, National Institutes of Health, 2007. Available at: http://www.nhlbi.nih. gov/guidelines/asthma/asthgdln.htm. Accessed January 2011.
3. GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, Global initiative for chronic obstructive lung disease (GOLD). 2010 Available at: http://www.goldcopd.org/download. asp?intId=608. Accessed February 2011.
4. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136:225-244.
5. Canadian Thoracic Society. Canadian Thoracic Society Guidelines for COPD. Available at http://www.copdguidelines.ca./. Accessed April 2011.
6. Dolovich MB, Dhand R. Aerosol drug delivery: Developments in design and clinical use. Lancet 2011; 377 (No 9770):1032-1045.
7. Ram FS, Brocklebank DM, Muers M, Wright J, Jones PW. Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease Cochrane Database Systematic Rev 2002;(1):CD002170.
8. Ram FS, Brocklebank DM, White J, Wright JP, Jones P. Pressurised metered dose inhalers versus all other hand-held inhaler devices to deliver beta2-agonist bronchodilators for non-acute asthma. Cochrane Database Systematic Rev 2002;(1):CD002158.
9. Dolovich M, Ahrens R, Hess D, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest 2005; 127:335-371.
10. Melani AS, Zanchetta D, Barbato N, et al. Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults. Ann Allergy Asthma Immunol 2004; 93:439-446. (Pubitemid 39507710)
11. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011; doi:10.1016/j. rmed.2011.01.005.
12. Restrepo RD, Alvarez MT, Wittnebel LD, Sorenson H, Wettstein R. Medication adherence issues in patients treated for COPD. Int J COPD 2008; 3(3):371-384.
13. Laube BL, Janssens HM, de Jongh FHC, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011; 37:1308-1331.
14. Kesser KC, Geller DE. New aerosol delivery devices for cystic fibrosis. Respir Care. 2009 Jun; 54(6):754-767; discussion 767-768.
15. Dhand R. Inhalation therapy in invasive and noninvasive mechanical ventilation. Curr Opin Crit Care 2007; 13:27-38. (Pubitemid 46061279)
16. Yu AP, Guerin A, Ponce de Leon D, et al. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ 2011;14:486-496.
17. van der Palen J, Klein JJ, van Herwaarden CL, Zielhuis GA, Seydel ER. Multiple inhalers confuse asthma patients. Eur Respir J 1999; 14:1034-1037.
18. Geller DE. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir Care 2005; 50:1313-21. (Pubitemid 46173315)
19. Newman SP. Inhaler treatment options in COPD. Eur Resp Rev 2005; 14:102-108. (Pubitemid 43028767)
20. Wildhaber JH, Devadason SG, Eber E, et al. Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants. Thorax 1996; 51(10):985-988. (Pubitemid 26360172)
21. Lauricella S, Dolovich M. The effects of inhalation delay and spacer pretreatment on HFA-pMDI delivery from several small volume valved holding chambers. J Aerosol Med 2007; 20:202.
22. McFadden ER. Improper patient techniques with metered dose inhalers: clinical consequences and solutions to misuse. J Allergy Clin Immunol 1995; 96:278-283.
23. Newman SP, Weisz AWB, Talaee N, Clarke SW. Improvement of drug delivery with a breath actuated pressurized aerosol for patients with poor inhaler technique. Thorax 2001; 46:712-16.
24. Mitchell JP, Nagel MW. Valved Holding Chambers (VHCs) for use with pressurized metered dose inhalers (pMDIs): a review of causes of inconsistent medication delivery. Prim Care Resp J 2007; 16(4): 7-14.
25. Rau JL. The inhalation of drugs: advantages and problems. Respir Care 2005; 50(3):367-382. (Pubitemid 46179556)
26. Hodder R, Price D. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat® Soft Mist™ Inhaler. Int J COPD 2009; 4:381-390.
27. Quinet P, Young CA, Heritier F. The use of dry powder inhaler devices by elderly patients suffering from chronic obstructive pulmonary disease. Ann Physical Rehab Med 2010; 53(2): 69-76.
28. Wieshammer S, Dreyhaupt J. Dry Powder Inhalers: Which Factors Determine the Frequency of Handling Errors? Respiration 2008; 75:18-25.
29. Corcoran TE, Dauber JH, Chigier N, Iacono AT. Improving drug delivery from medical nebulizers: the effects of increased nebulizer flow rates and reservoirs. J Aerosol Med 2002; 15;271-282. (Pubitemid 34983133)
30. Rau JL, Ari A, Restrepo RD. Performance comparison of nebulizer designs: constant-output, breath-enhanced, and dosimetric. Respir Care 2004; 49:174-179.
31. Dhand R, Giri VV, Noth I, Lissin D, Fishman RS, Taylor K. Bronchodilator response to ipratropium delivered via Aerodose inhaler or Pari LC Plus nebulizer in COPD. Am J Respir Crit Care Med 2002; 165:A593.
32. Abdelrahim ME, Plant P, Chrystyn H. In-vitro characterization of the nebulized dose during non-invasive ventilation. J Pharmacy Pharmacol 2010; 62:966-972.
33. de Moraes Souza ML, Meneghini AC, Ferraz E, Vianna EO, Borges MC. Knowledge of and technique for using inhalation devices among asthma patients and COPD patients. J Bras Pneumol 2009; 35(9):824-831.
34. American Association of Respiratory Care Aerosol Delivery Guide. Available at http://www.aarc.org/education/aerosol-devices/aerosol-delivery guide2.pdf. Accessed September 2011.
35. American College of Chest Physicians Patient Guides: Patient Instructions for Inhaled Devices. Available at http://www. chestnet.org/accp/patient-guides/ patient-instructions-inhaled-devices-english-and-spanish. Accessed September 2011.
36. Anderson P. Use of Respimat® Soft Mist™ Inhaler in COPD patients. Int J COPD. 2006; 1(3):251-259.
37. GfK Market Measures. COPD ATU, Q4 2008;Q 1g.
38. COPD e-Newsletter. Available at http://www.nhlbi.nih.gov/health/public/ lung/copd/. Accessed April 2011.
39. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178:332-338.
40. British Thoracic Society. Guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52:S1-S28.
41. ATS/ERS Task Force. Standards for the diagnosis and management of patients with COPD. American Thoracic Society and European Respiratory Society 2004. Available at: www.thoracic.org/clinical/copd-guidelines/resources/copddoc. pdf. Accessed February 2011.
42. Colice GL. Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease. Am J Med 1996; 100 (Suppl 1A): 11-18.
43. Friedman M. A multicenter study of nebulized bronchodilator solutions in chronic obstructive pulmonary disease. Am J Med. 1996; 100 (Suppl 1A): 30-39.
44. Brophy C, Kastelik JA, Gardiner E, Greenstone MA. Quality of life measurements and bronchodilator responsiveness in prescribing nebulizer therapy in COPD. Chronic Respir Dis 2008; 5:13-18. (Pubitemid 351903615)
45. The COMBIVENT Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997; 112:1514-1521.
46. Gross N, Tashkin D, Miller R, Oren J, Coleman W, Linberg S. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group. Respiration 1998; 65:354-362. (Pubitemid 28491270)
47. Levin DC, Little KS, Laughline KR, et al. Addition of anticholinergic solution prolongs bronchodilator effect of β2 agonists in patients with chronic obstructive pulmonary disease. Am J Med 1996; 100 (Suppl 1A): 40-48.
48. Tashkin DP, Bleecker E, Braun S, et al. Results of a multicenter study of nebulized inhalant bronchodilator solutions. Am J Med 1996; 100 (Suppl 1A):62-69.
49. Tashkin DP, Klein GL, Colman SS, Zayed H, Schonfeld WH. Comparing COPD treatment: Nebulized, metered dose, inhaler, and concomitant therapy. Am J Med 2007; 120:435-441. (Pubitemid 46627443)
50. Baumgartner RA, Hanania NA, Calhoun WJ, et al. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Therap 2007; 29:261-278.
51. Donohue JF, Hanania NA, Fogarty C, et al. Long-term safety of nebulized formoterol: Results of a twelve-month open label clinical trial. Ther Adv Respir Dis 2008a; 2:199-208.
52. Donohue JF, Hanania NA, Sciarappa KA, et al. Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: A one year evaluation of safety and tolerance. Therap Adv Respir Dis 2008b: 2:37-48. (Pubitemid 351472129)
53. Gross N, Nelson HS, Lapidus RJ, et al. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. Respir Med 2008; 102:189-197.
54. Hanania NA, Boota A, Kerwin E, Tomlinson L, Denis-Mize K. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. Drugs 2009; 69:1205-1216.
55. Hanania NA, Donohue JF, Nelson H, et al. The safety and efficacy of arformoterol and formoterol in COPD. COPD 2010; 7:17-31.
56. Hanrahan JP, Hanania NA, Calhoun WJ, et al. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. COPD 2008; 5:25-34. (Pubitemid 351225522)
57. Sutherland ER, Brazinsky S, Feldman G, et al. Nebulized formoterol effect on bronchodilation and satsfaction in COPD patients compared to QID ipratropium/albuterol MDI. Curr Med Res Opin 2009; 25:653-661.
58. Tashkin DP, Littner M, Andrews CP, et al. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med 2008; 102:479-487.
59. Paggiaro PL, Vagaggini B, DiFranco A, et al. Efficacy of nebulized flunisolide combined with salbutamol and ipratropium bromide in stable patients with moderate-to-severe chronic obstructive pulmonary disease. Respiration 2006; 73:603-609. (Pubitemid 44481476)
60. BROVANA® (arformoterol tartrate) Inhalation Solution 15 mcg/2mL. Prescribing Information. Sunovion Pharmaceuticals, Inc., Marlborough, MA.
61. Perforomist® (formoterol fumarate) Inhalation Solution 20 mcg/2mL Prescribing Information. Dey Pharma LP, Basking Ridge, NJ.
62. Pulmicort Respules® (budesonide inhalation suspension). Prescribing Information. AstraZeneca LP, Wilmington DE.
63. Hurst JR, Vestbo J, Anzueto A, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363:1128-1138.
64. Calverley PM, Rennard S, Nelson HS, et al. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respir Res 2008; 9(1):73.
65. Goodman DE, Israel E, Rosenberg M, et al. The influence of age, diagnosis, and gender on proper use of metered-dose inhalers. Am J Respir Crit Care Med 1994; 150:1256-1261. (Pubitemid 24356637)
66. Barta SK, Crawford A, Roberts CM. Survey of patients views of domiciliary nebulizer treatment for chronic lung disease. Respir Med 2002; 96:375-381. (Pubitemid 36443152)
67. Marcus P. The role of nebulized inhaled corticosteroid therapy in adult patients with asthma and chronic obstructive pulmonary disease. Adv Ther 2005; 22(4):407-418. (Pubitemid 43003330)
68. Dhand R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir Care 2002; 47:1406-1416.
69. Stoller JK. Clinical practice: acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 346:988-994. (Pubitemid 34983250)
70. McCrory DC, Brown LE. Anticholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease (review). The Cochrane Library 2003(issue 1):1-24.
71. Snow V, Lascher S, Mottur-Pilson C, Joint Expert Panel on Chronic Obstructive Pulmonary Disease of the American College of Chest Physicians and the American College of Physicians-American Society of Internal Medicine. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2001; 134:595-599. (Pubitemid 32245322)
72. Bach PB, Brown C, Gelfand SE, McCrory DC. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med 2001; 134:600-620. (Pubitemid 32245323)
73. Cydulka RK, Emerman CL. Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1995; 25:470-473.
74. ODriscoll, BR, Taylor, RJ, Horsley, MG, Chambers DK, Bernstein A. Nebulised salbutamol with and without ipratropium bromide in acute airflow obstruction. Lancet 1989; 1:1418-1420.
75. Karpel, JP. Bronchodilator responses to anticholinergic and beta-adrenergic agents in acute and stable COPD. Chest 1991; 99:871-876.
76. Khoukaz G, Gross NJ. Effects of salmeterol on arterial blood gases in patients with stable chronic obstructive pulmonary disease: comparison with albuterol and ipratropium. Am J Respir Crit Care Med 1999; 160:1028-1030. (Pubitemid 29442048)
77. Polverino E, Gomez FP, Manrique H, et al. Gas exchange response to short-acting-2-agonists in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2007; 176:350-355.
78. Suissa S, Assimes T, Ernst P. Inhaled short acting beta agonist use in COPD and the risk of acute myocardial infarction. Thorax 2003; 58:43-46. (Pubitemid 36135357)
79. Stockley RA, Chopra N, Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax 2006; 61:122-28. (Pubitemid 43235428)
80. Stockley RA, Whitehead PJ, Williams MK. Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis. Respir Res 2006b; 7:147.
81. Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003; 290:2301-2312. (Pubitemid 37430563)
82. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005; 143:317-326.
83. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115:957-965. (Pubitemid 29193661)
84. Cazzola M, Santus P, Matera MG, et al. A single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD. Respir Med 2003; 97:458-462. (Pubitemid 36519515)
85. Di MF, Verga M, Santus P, et al. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respir Med 2006; 100:1925-1932. (Pubitemid 44490293)
86. Colice GL, Carnathan B, Sung J, Paramore LC. A respiratory therapist-directed protocol for managing inpatients with asthma and COPD incorporating a long-acting bronchodilator. J Asthma 2005; 42:29-34. (Pubitemid 40365726)
87. Drescher GS, Carnathan BJ, Imus S, Colice GL. Incorporating tiotropium into a respiratory therapist-directed bronchodilator protocol for managing in-patients with COPD exacerbations decreases bronchodilator costs. Respir Care 2008; 53:1678-1684.
88. Quon, BS, Gan, WQ, Sin, DD. Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis. Chest 2008; 133:756-766. (Pubitemid 351367386)
89. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999; 340:1941-1947. (Pubitemid 29288269)
90. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354:456-460. (Pubitemid 29368923)
91. Lindenauer, PK, Pekow, PS, Lahti MC, et al. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA 2010; 303:2359-2367.
92. de Jong YP, Uil SM, Grotjohan HP, et al. Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. Chest 2007; 132:1741-1747.
93. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57:847-852. (Pubitemid 35178607)
94. Wilkinson TMA, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 1298-1303. (Pubitemid 39571857)
95. Johansson SA, Andersson KE, Brattsand R, Gruvstad E, Hedner P. Topical and systemic glucocorticoid potencies of budesonide, beclomethasone dipropionate and prednisolone in man. Eur J Respir Dis Suppl 1982; 122:74-82. (Pubitemid 13235841)
96. Brogden RN, McTavish D. Budesonide: an updated review of its pharmacological properties and therapeutic efficacy in asthma and rhinitis. Drugs 1992; 44:375-407.
97. Walsh LJ, Wong CA, Oborne J, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 2001; 56:279-284. (Pubitemid 32269807)
98. Jones A, Fay JK, Burr M, et al. Inhaled corticosteroid effect on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002; CD003537.
99. Richy F, Bousquet J, Ehrlich GE, et al. Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporos Int 2003; 14:179-190. (Pubitemid 40826230)
100. Belda J, Margarit G, Martinez C, et al. Anti-inflammatory effects of high-dose inhaled fluticasone versus oral prednisone in asthma exacerbations. Eur Respir J 2007; 30:1143-1149. (Pubitemid 351194762)
101. Rodrigo GJ. Comparison of inhaled fluticasone with intravenous hydrocortisone in the treatment of adult acute asthma. Am J Respir Crit Care Med 2005; 171:1231-1236. (Pubitemid 40740729)
102. Levy ML, Stevenson C, Maslen T. Comparison of short courses of oral prednisolone and fluticasone propionate in the treatment of adults with acute exacerbations of asthma in primary care. Thorax 1996; 51:1087-1092. (Pubitemid 26402819)
103. Morice AH, Morris D, Lawson-Matthew B. A comparison of nebulized budesonide with oral prednisolone in the treatment of exacerbations of obstructive pulmonary disease. Clin Pharmacol Ther 1996; 60:675-678. (Pubitemid 27025915)
104. Maltais F, Ostinelli J, Bourbeau J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 165:698-703. (Pubitemid 34194760)
105. Mirici A, Akgun M. Comparison of the efficacy of nebulized budesonide with parenteral corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clin Drug Invest 2003; 23:55-62. (Pubitemid 36143338)
106. Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G. The role of nebulized budesonide in the treatment of exacerbations of COPD. Eur Respir J 2007; 29:660-667. (Pubitemid 46554614)
107. Rodrigo G, Rodrigo C. Inhaled flunisolide for acute severe asthma. Am J Respir Crit Care Med 2000; 157:698-703.
108. McKenzie JE, Cruz-Rivera M. Compatibility of budesonide inhalation suspension with four nebulizing solutions. Ann Pharmacother 2004; 38:967-972. (Pubitemid 38657735)